Evidence map›Paper›PMID 35310881›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2020

Cell-mediated immune resistance in cancer.

Yuhao Wang, Emily Hays, Martina Rama, Benjamin Bonavida

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Molecular Mechanisms of Drug Resistance in Glioblastoma.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Why nanodiamond carriers manage to overcome drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuhao WangDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, The University of California, Los Angeles, Los Angeles, CA 90025-1747, USA.
Emily HaysDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, The University of California, Los Angeles, Los Angeles, CA 90025-1747, USA.
Martina RamaDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, The University of California, Los Angeles, Los Angeles, CA 90025-1747, USA.
Benjamin BonavidaDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, The University of California, Los Angeles, Los Angeles, CA 90025-1747, USA.
University of California, Los Angeles · US

Funding

UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
NCI NIH HHS T32 CA009120
6 · The paper itself

Abstract

The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refractory to clinically established and experimental immunotherapies, including monoclonal antibodies and T cell-based therapies. From various forms of cytotoxic T cells to small molecule inhibitors that revamp the tumor microenvironment, these therapies have demonstrated notable responses in cancer models and a resistant subset of cancer patients, used both alone and in combination. However, even current approaches, such as those targeting checkpoint molecules, tumor ligands, and involving gene-related therapies, present a challenge in non-responding patients. In this perspective, we discuss the most common mechanisms of immune resistance, including tumor heterogeneity, tumor ligand and major histocompatibility complex modulation, anti-apoptotic pathways, checkpoint inhibitory ligands, immunosuppressive cells and factors in the tumor microenvironment, and activation-induced cell death. In addition, we discuss the strategies designed to circumvent these resistance pathways to showcase the potential of emerging technologies in battling the rise of resistance.

Indexed as

cancercheckpoint inhibitorsheterogeneityimmune resistanceImmune systemsurvival pathwaysT cellstumor microenvironment

Identifiers

PMID35310881
PMCPMC8932590
OpenAlexW2998624350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.